Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives $6.67 Consensus PT from Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been assigned a consensus rating of “Hold” from the five analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $6.6667.

SRTS has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a research report on Thursday, January 22nd. Wall Street Zen cut shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Finally, Maxim Group cut their target price on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th.

Sensus Healthcare Price Performance

Shares of SRTS stock opened at $4.41 on Monday. Sensus Healthcare has a fifty-two week low of $3.03 and a fifty-two week high of $5.92. The stock’s 50-day moving average is $4.52 and its two-hundred day moving average is $3.88. The firm has a market cap of $72.41 million, a P/E ratio of -9.38 and a beta of 1.22.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.10). Sensus Healthcare had a negative net margin of 28.09% and a negative return on equity of 14.82%. The firm had revenue of $4.94 million during the quarter, compared to the consensus estimate of $8.35 million. As a group, research analysts expect that Sensus Healthcare will post 0.32 EPS for the current year.

Institutional Investors Weigh In On Sensus Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in SRTS. Divisadero Street Capital Management LP raised its position in shares of Sensus Healthcare by 459.4% in the second quarter. Divisadero Street Capital Management LP now owns 324,673 shares of the company’s stock valued at $1,539,000 after purchasing an additional 266,635 shares during the period. Greenline Wealth Management LLC acquired a new position in Sensus Healthcare in the 4th quarter valued at $513,000. Rothschild Wealth LLC acquired a new position in Sensus Healthcare in the 4th quarter valued at $500,000. Pacific Ridge Capital Partners LLC raised its holdings in Sensus Healthcare by 21.8% in the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock worth $2,781,000 after acquiring an additional 125,245 shares during the period. Finally, Ingalls & Snyder LLC acquired a new position in Sensus Healthcare during the 4th quarter worth $219,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.